Consensus molecular subtypes of CRC
| Consensus Molecular Subtypes of CRC | ||
|---|---|---|
| Subtype | Features | Percent of Total |
| CMS1 (MSI immune) | Hypermutated Microsatellite instability Strong immune activation | 14% |
| CMS2 (canonical) | Epithelial Chromosomally unstable Marker Wnt and MYC activation | 37% |
| CMS1 (metabolic) | Metabolic Evident metabolic dysregulation | 13% |
| CMS1 (mesenchymal) | Prominent TGF-β activation Stromal invasion Angiogenesis | 23% |
An international consortium led by Guinney at Fred Hutchinson Cancer Research Center and other institutions has grouped molecular subtypes of CRC into a classification as the future basis for subtype-based targeted interventions.35